menu
    • menu
    [{"orgOrder":0,"company":"Bandim Health Project","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GUINEA-BISSAU","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dihydroartemisinin","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Bandim Health Project","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bandim Health Project \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bandim Health Project \/ Undisclosed"},{"orgOrder":0,"company":"National Institute for Medical Research, Tanzania","sponsor":"Ministry of Health and Social Welfare, Tanzania | World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TANZANIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dihydroartemisinin","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"National Institute for Medical Research, Tanzania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute for Medical Research, Tanzania \/ Ministry of Health and Social Welfare, Tanzania | World Health Organization","highestDevelopmentStatusID":"11","companyTruncated":"National Institute for Medical Research, Tanzania \/ Ministry of Health and Social Welfare, Tanzania | World Health Organization"},{"orgOrder":0,"company":"Kunming Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dihydroartemisinin","moa":"Ferriprotoporphyrin IX","graph1":"Immunology","graph2":"Phase II","graph3":"Kunming Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kunming Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kunming Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Malaria Consortium","sponsor":"National Centre for Parasitology, Entomology and Malaria Control, Cambodia | Institute Pasteur, Cambodia | World Health Organization | Centers for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dihydroartemisinin","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Malaria Consortium","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Malaria Consortium \/ National Centre for Parasitology, Entomology and Malaria Control, Cambodia | Institute Pasteur, Cambodia | World Health Organization | Centers for Disease Control and Prevention","highestDevelopmentStatusID":"11","companyTruncated":"Malaria Consortium \/ National Centre for Parasitology, Entomology and Malaria Control, Cambodia | Institute Pasteur, Cambodia | World Health Organization | Centers for Disease Control and Prevention"},{"orgOrder":0,"company":"Liverpool School of Tropical Medicine","sponsor":"University of Bergen | University of Malawi | Makerere University | Indiana University | Global Health Uganda","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dihydroartemisinin","moa":"Ferriprotoporphyrin IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liverpool School of Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liverpool School of Tropical Medicine \/ University of Bergen | University of Malawi | Makerere University | Indiana University | Global Health Uganda","highestDevelopmentStatusID":"10","companyTruncated":"Liverpool School of Tropical Medicine \/ University of Bergen | University of Malawi | Makerere University | Indiana University | Global Health Uganda"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Ministry of Health, Swaziland | Clinton Health Access Initiative, Eswatini | University of Texas System","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dihydroartemisinin","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Ministry of Health, Swaziland | Clinton Health Access Initiative, Eswatini | University of Texas System","highestDevelopmentStatusID":"10","companyTruncated":"University of California, San Francisco \/ Ministry of Health, Swaziland | Clinton Health Access Initiative, Eswatini | University of Texas System"},{"orgOrder":0,"company":"PATH","sponsor":"Ministry of Health, Zambia | AKROS Global Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dihydroartemisinin","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"PATH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PATH \/ Ministry of Health, Zambia | AKROS Global Health","highestDevelopmentStatusID":"11","companyTruncated":"PATH \/ Ministry of Health, Zambia | AKROS Global Health"},{"orgOrder":0,"company":"PATH","sponsor":"Federal Minstry of Health of Ethiopia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dihydroartemisinin","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PATH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PATH \/ Federal Minstry of Health of Ethiopia","highestDevelopmentStatusID":"10","companyTruncated":"PATH \/ Federal Minstry of Health of Ethiopia"}]

    Find Clinical Drug Pipeline Developments & Deals for Dihydroartemisinin

    Menu

    Dihydroartemisinin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PATH

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PATH

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Federal Minstry of Health of Ethiopia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, Ethiopia

                            Details : Dihydroartemisinin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Plasmodium falciparum.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 23, 2024

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Federal Minstry of Health of Ethiopia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bandim Health Project

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Bandim Health Project

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for Treating Malari...

                            Details : Dihydroartemisinin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Malaria.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 24, 2021

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Liverpool School of Tropical Medicine

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Liverpool School of Tropical Medicine

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : University of Bergen | University of Malawi | Makerere University | Indiana University | Global Health Uganda

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell...

                            Details : Dihydroartemisinin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia, Sickle Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 14, 2021

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : University of Bergen | University of Malawi | Makerere University | Indiana University | Global Health Uganda

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kunming Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kunming Pharmaceuticals

                            China arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Exploratory Study of DHA in Systemic Lupus Erythematosus Patients

                            Details : Dihydroartemisinin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lupus Erythematosus, Systemic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 11, 2018

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PATH

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            PATH

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Ministry of Health, Zambia | AKROS Global Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Community-led Responses for Elimination: Controlled Trial of Reactive Case Detection Versus Reactive Drug Admi...

                            Details : Dihydroartemisinin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Malaria.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 13, 2016

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Ministry of Health, Zambia | AKROS Global Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            National Institute for Medical Research, Tanzania

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            National Institute for Medical Research, Tanzania

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Ministry of Health and Social Welfare, Tanzania | World Health Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Unco...

                            Details : Dihydroartemisinin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Malaria.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 29, 2015

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Ministry of Health and Social Welfare, Tanzania | World Health Organization

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Malaria Consortium

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Malaria Consortium

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : National Centre for Parasitology, Entomology and Malaria Control, Cambodia | Institute Pasteur, Cambodia | World Health Organization | Centers for Disease Control and Prevention

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Tolerability of Low Dose Primaquine

                            Details : Dihydroartemisinin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Malaria, Falciparum.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 06, 2015

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : National Centre for Parasitology, Entomology and Malaria Control, Cambodia | Institute Pasteur, Cambodia | World Health Organization | Centers for Disease Control and Prevention

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            University of California, San Francisco

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of California, San Francisco

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Ministry of Health, Swaziland | Clinton Health Access Initiative, Eswatini | University of Texas System

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland

                            Details : Dihydroartemisinin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Malaria.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 12, 2014

                            Lead Product(s) : Dihydroartemisinin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Ministry of Health, Swaziland | Clinton Health Access Initiative, Eswatini | University of Texas System

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth